Phanes Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Spevatamig in Combination with Chemotherapy for the Frontline Treatment of Metastatic Pancreatic Ductal Adenocarcinoma
Two dose levels of spevatamig in combination with standard of care chemotherapy are being evaluated as frontline (1L) treatment for metastatic pancreatic ductal adenocarcinoma (PDAC) in the Phase 2 study. Initial data were presented at the 2026 American Society of Clinical Oncology (ASCO)...
Two dose levels of spevatamig in combination with standard of care chemotherapy are being evaluated as frontline (1L) treatment for metastatic pancreatic ductal adenocarcinoma (PDAC) in the Phase 2 study. Initial data were presented at the 2026 American Society of Clinical Oncology (ASCO)...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.